FDA Approved: OZEMPIC — Supplemental Application (Novo Nordisk)

View source ↗

Summary

FDA approved a supplemental application for Ozempic (oral semaglutide) submitted by Novo Nordisk. The action concerns the oral formulation related to Ozempic.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• OZEMPIC (semaglutide)

Snippet

SUPPL AP for OZEMPIC (ORAL SEMAGLUTIDE)